Powers Advisory Group LLC Cuts Stake in Pfizer Inc. $PFE

Powers Advisory Group LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,408 shares of the biopharmaceutical company’s stock after selling 537 shares during the period. Powers Advisory Group LLC’s holdings in Pfizer were worth $325,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its holdings in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi grew its holdings in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC acquired a new position in Pfizer during the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. grew its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after acquiring an additional 7,581,030 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 6.8%

Shares of Pfizer stock opened at $25.46 on Wednesday. The company has a market cap of $144.75 billion, a P/E ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The firm has a fifty day moving average of $24.55 and a two-hundred day moving average of $24.11.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.